Stratasys completes US rollout of 3D-printed imaging support material

SSYS -1.48% SEMHF +0.53%

Stratasys’3D printed RadioMatrix technology is now fully available in the US, offering clinicians a platform to create radio-realistic models.

Made of a material called radiopaque, RadioMatrix is claimed to be the first 3D printed material that delivers control over radiopacity. This enables clinicians can produce patient-specific models with ‘fully tuneable’ visibility on X-ray-based imaging.

Applicable for image-based training and surgical planning, 3D printing specialist Stratasys said the material aims to create more controlled, repeatable environments for research.

Stratasys's healthcare vice-president Erez Ben-Zvi called the full US commercialisation of RadioMatrix a “major step” in advancing imaging education and training.

Ben-Zvi said: “By giving radiologists and device manufacturers the ability to print ultra-realistic, customised radiographically accurate models, we’re helping replace traditional phantom solutions and reliance on cadavers with customisable, repeatable, and scalable alternatives."

In February 2025, Stratasys and Siemens Healthineers presented data from a collaboration which showed that 3D printed RadioMatrix ‘phantoms’ were able to closely replicate real human tissue in CT imaging, with reported deviations as low as single Hounsfield units (HU) in critical areas such as grey matter and veins.

The companies’ work found that anatomically realistic, radio-accurate phantoms could preserve fine anatomical details and pathological variations specific to individual patients.

Siemens Healthineers paired its imaging algorithms with Stratasys’ 3D printed material to improve how radiologists validate and optimise CT protocols, along with accelerating the development of new imaging algorithms for more precise diagnosis and treatment planning.

According to GlobalData analysis, the medical 3D printing market is growing at a compound annual growth rate (CAGR) of 21% and is forecast to reach a market valuation of $4bn in 2026, up from $2bn in 2022.

Beyond imaging-related training protocols, in the healthcare space, 3D printing is driving change in the planning of, and assistance during surgical procedures. Research published in Academic Radiology has indicated that the use of 3D anatomic models as surgical guides reduced surgical time by a mean of 62 minutes and resulted in cost savings of $3,720 per case.

In other healthcare segments, Stratasys is involved in a collaboration with CollPlant Biotechnologies to develop 3D-printed breast implants while US-based biotechnology company FluidForm Bio is working to advance 3D-printing of human cardiac tissue using freeform reversible embedding of suspended hydrogels (FRESH) 3D bioprinting.

"Stratasys completes US rollout of 3D-printed imaging support material" was originally created and published by Medical Device Network, a GlobalData owned brand.

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.